Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly Completes Acquisition

Wednesday, March 1, 2017 11:02 AM EDT Updated: Wednesday, March 1, 2017 02:05 PM EDT
By Alex Brown
Lilly Completes Acquisition Lilly completed the CoLucid acquisition in March.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is growing with a major acquisition. The company has completed its $960 million deal with Massachusetts-based CoLucid Pharmaceuticals Inc. (Nasdaq: CLCD), which is currently developing a migraine treatment originally discovered at Lilly.

When the acquisition was originally announced in January, Lilly Chief Executive Officer David Ricks said the deal will enhance the company’s pain management portfolio. The oral migraine treatment, known as lasmiditan, is expected to begin the second of two Phase 3 trials in the second half of the year.

"More than 36 million people suffer from migraine in the United States alone, and lasmiditan could represent the first significant innovation for the acute treatment of migraine in more than 20 years," said Ricks.

Lilly out-licensed the treatment to CoLucid in 2005. The company said in January if the second trial is successful, it could submit for U.S. regulatory approval in 2018.

As a result of the acquisition, CoLucid’s common stock will no longer be traded on the Nasdaq. Lilly did not state whether any jobs would be affected by the deal.

Story Continues Below

Most Popular Stories

  • Iconic ‘Hoosiers’ trophy gets new permanent home

  • Deep frozen storage facility opens in Greenfield

  • Startup lands $30M in funding to commercialize cancer imaging agent

  • IndyGo CEO leaving after four years leading transit agency

  • Performance management plays a key role in employee engagement

  • New president for Toyota Indiana

Perspectives

Performance management plays a key role in employee engagement

Performance management plays a key role in employee engagement

Employee engagement is a catchall term that refers to the degree to which employees are committed to their work and their organization. We all know that engaged employees are more productive, more creative, and more likely to stay with their organization. So, how does performance management impact employee engagement?...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service